The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS ANNOUNCES PARTNERSHIP

11 Apr 2018 07:00

RNS Number : 4904K
Flying Brands Limited
11 April 2018
 

 

 

FLYING BRANDS' SUBSIDIARY IMAGING BIOMETRICS ANNOUNCES DISTRIBUTION PARTNERSHIP WITH AI EXCHANGE PLATFORM, ENVOY AI

 

IB Neuro and IB Delta T1 Maps are now available on EnvoyAI's artificial intelligence Exchange

 

 

Flying Brand's newly acquired subsidiary Imaging Biometrics®, LLC ("IB"), a medical imaging software company specialising in advanced visualisation and analytics, has entered into a distribution agreement with EnvoyAI, a leading artificial intelligence ("AI") Exchange platform. IB Neuro, the premier magnetic resonance ("MR") imaging dynamic susceptibility contrast (DSC) perfusion solution, and IB's Delta T1 mapping algorithm, are now available for purchase on the EnvoyAI Exchange.

 

Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

 

"This partnership with EnvoyAI enables immediate and widespread access to our proven and quantitative imaging biomarkers for neuro radiologists, neuro-oncologist, and neuro surgeons," said Michael Schmainda, CEO of IB. "The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment. We are delighted to participate on the EnvoyAI Exchange and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients."

 

About EnvoyAI (www.envoyai.com)

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialisation processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Imaging Biometrics® LLCImaging Biometrics develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands PLC

Flying Brands PLC (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGMDVGGGRZM
Date   Source Headline
21st Apr 20117:00 amRNSContract win with Debenhams
13th Apr 20117:00 amRNSTrading Statement
10th Mar 201110:42 amRNSProposed Dividend - Clarification
10th Mar 20117:00 amRNSFinal Results
20th Jan 20111:43 pmRNSAcquisition
14th Jan 20117:00 amRNSTrading Statement
17th Nov 20101:36 pmRNSAdditional Directorship for John Henwood
26th Oct 20107:00 amRNSInterim Management Statement
26th Oct 20107:00 amRNSInterim Management Statement
4th Oct 201012:25 pmRNSBlocklisting Interim Review
19th Aug 20107:00 amRNSCompletion of Acquisition of Garden Centre Online
11th Aug 20107:00 amRNSHalf Yearly Report
26th Jul 20101:56 pmRNSNotice of Results
24th May 201012:28 pmRNSAcquisition
12th May 201010:19 amRNSResult of AGM
12th May 20107:00 amRNSTrading Update
21st Apr 20101:32 pmRNSDirector/PDMR Shareholding
21st Apr 20107:00 amRNSDirector/PDMR Shareholding
20th Apr 201010:27 amRNSAdjournment of AGM
20th Apr 20109:09 amRNSReplacement Interim Management Statement
20th Apr 20107:00 amRNSInterim Management Statement
8th Apr 201011:12 amRNSDirector Update
1st Apr 201011:08 amRNSBlocklisting Interim Review
11th Mar 20107:00 amRNSFinal Results
13th Jan 20107:00 amRNSTrading Statement
19th Oct 20097:00 amRNSInterim Management Statement
15th Oct 20097:00 amRNSPlacing of Shares
1st Oct 20097:00 amRNSStrategic changes at Flying Flowers
30th Sep 20099:32 amRNSBlocklisting Interim Review
8th Sep 20093:08 pmRNSIssue of shares
31st Jul 20097:00 amRNSHalf Yearly Report
7th May 20092:23 pmRNSDirectorate Change
27th Apr 20097:00 amRNSDirector/PDMR Shareholding
22nd Apr 200910:01 amRNSAGM & Interim Management Statement
16th Apr 20099:55 amRNSDirector/PDMR Shareholding
30th Mar 20096:29 pmRNSBlocklisting Interim Review
13th Mar 20097:00 amRNSFinal Results
18th Feb 20097:00 amRNSDirectorate Change
21st Jan 20097:00 amRNSTrading Statement
10th Dec 200810:00 amRNSDirector/PDMR Shareholding
21st Nov 20087:10 amRNSOffer Talks Terminated
21st Nov 20087:00 amRNSStatement re Possible Offer
18th Nov 20088:28 amRNSEPT Disclosure
12th Nov 200810:24 amRNSEPT Disclosure with Trade Amendment
11th Nov 20088:40 amRNSEPT Disclosure
6th Nov 20088:46 amRNSEPT Disclosure
5th Nov 20089:09 amRNSEPT Disclosure
3rd Nov 20089:12 amRNSEPT Disclosure
31st Oct 20089:47 amRNSEPT Disclosure
29th Oct 20088:45 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.